Classical Hodgkin or Mediastinal MK-3475A-F65
Study #MK-3475A-F65Description
A Phase 2 Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Pembrolizumab Coformulated With Hyaluronidase in Participants with Relapsed or Refractory Classical Hodgkin Lymphoma or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma.
Interested in this trial? Email [email protected].
Back To Clinical Trials